Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Abstract

Abstract Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.

Keywords

Affiliated Institutions

• University Hospital Ulm DE
• King's College London GB
• Medical Research Council GB
• The University of Texas MD Anderson Cancer Center US
• Presbyterian Hospital US
• University of Oxford GB
• National Health Service GB
• Weill Cornell Medicine US
• National Institutes of Health US
• Klinik und Poliklinik für Psychotherapie und Psychosomatik DE
• University of Rome Tor Vergata IT
• Munich Leukemia Laboratory (Germany) DE
• New York Hospital Queens US
• NewYork–Presbyterian Hospital US
• Fred Hutch Cancer Center US
• University of Birmingham GB
• Amsterdam UMC Location Vrije Universiteit Amsterdam NL
• University of Washington US
• Cornell University US
• Cardiff University GB
• Oxford University Hospitals NHS Trust GB
• Radboud University Medical Center NL
• Lille’s Cardiology Hospital FR
• Medizinische Hochschule Hannover DE
• Centre Hospitalier Universitaire de Nantes FR
• Radboud University Nijmegen NL

Related Publications